37
Participants
Start Date
March 1, 2021
Primary Completion Date
October 1, 2022
Study Completion Date
January 1, 2024
Emtricitabine (FTC)/Tenofovir Disoproxil (TDF)
Emtricitabine (FTC) 200 mg/Tenofovir Disoproxil (TDF) 300 mg by mouth once per day
Raltegravir
Raltegravir (RTF) 600 mg two tablets by mouth once per day
Placebo Oral Capsule [CEBOCAP]
Two capsules identical to Raltegravir and one capsule identical to Truvada with no active ingredients by mouth once per day
University of Alberta, Edmonton
St Paul's Hospital, University of British Columbia, Vancouver
Vancouver General Hospital, University of Brittish Columbia, Vancouver
University of Toronto, Toronto
University of Montreal, Montreal
Royal University Hospital, Saskatoon
Merck Sharp & Dohme LLC
INDUSTRY
University of Alberta
OTHER